Category: Cell and Gene Therapy

September 13, 2021

While estimates vary, AMD is thought to affect a large number of people. A study published in 2014, for instance, projected the patient population globally would hit 196 million in 2020 and grow to 288 million by 2040. Among those […]

September 9, 2021

Obsidian Therapeutics has raked in $115 million to realize the long-unfulfilled therapeutic promise of tumor-infiltrating lymphocytes (TILs). The series B gives Obsidian a shot at showing whether freeing TILs from IL-2 can finally unleash power that research has hinted at […]

September 7, 2021

The theoretical risk that gene therapy may cause cancer in humans has hung over the field for decades. Those worries resurfaced last year when a liver tumor was spotted in a patient who had received an experimental treatment for hemophilia […]

September 1, 2021

The ASPIRO trial of AT132 has been paused after abnormal liver function tests (LFTs) were seen in a patient receiving the gene therapy, and information on the adverse event has been shared with regulators, according to the drugmaker. ASPIRO was […]

August 25, 2021

CAR-T cell therapies, which involve engineering a patient’s own T cells to target and kill cancer cells bearing specific antigens, has shown strong results in blood disorders. But many patients still progress or relapse after initial remission, because tumor cells […]

August 24, 2021

Recent interest in gene therapies and the genetic constructs on which they are based is causing a flurry of activity in facility construction and expansion. After they are manufactured doses must be stored, shipped, and stored again as they await […]

August 19, 2021

The amount of money flowing into cell and gene therapy development suggests investor confidence in the field’s future remains high, even as clinical, regulatory and commercial setbacks have hindered a number of companies, such as Bluebird bio, Biogen and Adverum […]

August 17, 2021

Innoforce Pharmaceuticals has opened a new advanced cell and gene therapy development facility in Hangzhou, China. Analytical development (AD) and process development (PD) represents a critical step towards providing services for potential clients in their cell and gene therapy product […]

August 17, 2021

Tendon injuries in sheep that were treated with stem cell grafts achieved, in just two months, a diameter and hardness similar to the original healthy tendon, according to the results of a study (“Adipose micro-grafts enhance tendinopathy healing in ovine […]

August 11, 2021

In a statement, the US biotech company’s president of severe genetic diseases Andrew Obenshain said bluebird will instead focus on the US market, highlighting the ‘challenges of achieving appropriate value recognition and market access for Zynteglo [betibeglogene autotemcel] in Europe’. […]

August 11, 2021

New market research states the global cell and gene therapy manufacturing services market will reach $13.8 billion by 2026, expanding at a compound annual growth rate (CAGR) of 12.4 percent from its current value of $7.7 billion (in 2021). The […]

August 9, 2021

The biopharmaceutical market, one of the fastest growing segments in the life sciences industry, is valued at approximately USD 325.17 billion in 2020(1). The segment is expected to continue its upward trajectory at a compound aggregate growth rate of 7.32% […]